Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Cancer Discovery|May 1, 2020
<i>EZH2</i>-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication StressTheresa E León, Tanya Rapoz-D'Silva, Cosetta Bertoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort StudyAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Blood|January 25, 2002
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty, Karl Peggs, Rajesh Chopra, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
The New England Journal of Medicine|January 21, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLAdam Ivey, Robert K Hills, Michael A Simpson, et al.
Blood|October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJosé A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
Glycobiology|March 10, 2011
G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunctionBu'hussain Hayee, Aristotelis Antonopoulos, Emma J Murphy, et al.
Blood|March 26, 2015
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemiaAndrea Kühnl, Peter J M Valk, Mathijs A Sanders, et al.
Blood|March 9, 2017
Activation of the <i>LMO2</i> oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemiaSunniyat Rahman, Michael Magnussen, Theresa E León, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Cancer Discovery|May 1, 2020
<i>EZH2</i>-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication StressTheresa E León, Tanya Rapoz-D'Silva, Cosetta Bertoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort StudyAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Blood|January 25, 2002
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty, Karl Peggs, Rajesh Chopra, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
The New England Journal of Medicine|January 21, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLAdam Ivey, Robert K Hills, Michael A Simpson, et al.
Blood|October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJosé A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
Glycobiology|March 10, 2011
G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunctionBu'hussain Hayee, Aristotelis Antonopoulos, Emma J Murphy, et al.
Blood|March 26, 2015
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemiaAndrea Kühnl, Peter J M Valk, Mathijs A Sanders, et al.
Blood|March 9, 2017
Activation of the <i>LMO2</i> oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemiaSunniyat Rahman, Michael Magnussen, Theresa E León, et al.
Pageof 13